<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00274885</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000454401</org_study_id>
    <secondary_id>GERCOR-TAUROX</secondary_id>
    <secondary_id>SANOFI-GERCOR-TAUROX</secondary_id>
    <secondary_id>EU-20573</secondary_id>
    <nct_id>NCT00274885</nct_id>
  </id_info>
  <brief_title>Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer</brief_title>
  <official_title>Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Learning about the relationship between platinum levels in the blood and
      neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients
      live more comfortably.

      PURPOSE: This phase IV trial is studying the relationship between platinum levels in the
      blood and neurotoxicity in patients who are receiving oxaliplatin for gastrointestinal
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the relationship between residual platinum levels in the blood and persistent
           neurotoxicity in patients receiving oxaliplatin for gastrointestinal cancer.

      Secondary

        -  Determine the pharmacokinetics of oxaliplatin in these patients.

      OUTLINE: This is an open-label, nonrandomized, multicenter study.

      Patients receive oxaliplatin IV over 2 hours. Treatment repeats every 2-3 weeks in the
      absence of disease progression or unacceptable toxicity.

      Neurological function and platinum levels in the blood are assessed at baseline, after each
      course of oxaliplatin, and at the end of study treatment.

      PROJECTED ACCRUAL: A total of 58 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2005</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship between residual platinum levels in the blood and persistent neurotoxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>management of therapy complications</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of gastrointestinal cancer

          -  Receiving or planning to receive 8 months of oxaliplatin-based chemotherapy

          -  No pre-existing neuropathy

          -  No CNS disease or cerebral metastases

        PATIENT CHARACTERISTICS:

          -  WHO 0-1

          -  Life expectancy â‰¥ 12 weeks

          -  No biliary or gastro-duodenal obstruction

          -  No familial, social, geographical, or psychological condition that would preclude
             study treatment

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No other concurrent drug or agent that is potentially neurotoxic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Lechat</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Pitie-Salpetriere</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Grenoble - Hopital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Rebischung</last_name>
      <phone>33-4-7676-5451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Universitaire Hop Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Hebbar, MD</last_name>
      <phone>33-3-2044-5461</phone>
      <email>m-hebbar@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Jean</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Lledo</last_name>
      <phone>33-4-7878-1051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Rosmorduc, MD, PhD</last_name>
      <phone>33-1-4928-2382</phone>
      <email>olivier.rosmorduc@sat.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Baptiste Meric, MD</last_name>
      <phone>33-1-4216-0471</phone>
      <email>jeanbaptiste.meric@psl.ap-hop-paris.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Andre, MD</last_name>
      <phone>33-1-6177-0708</phone>
      <email>thierry.andre@tnn.ap-hop-paris.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2006</study_first_submitted>
  <study_first_submitted_qc>January 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2006</study_first_posted>
  <last_update_submitted>December 2, 2011</last_update_submitted>
  <last_update_submitted_qc>December 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2011</last_update_posted>
  <keyword>neurotoxicity</keyword>
  <keyword>carcinoma of the appendix</keyword>
  <keyword>recurrent anal cancer</keyword>
  <keyword>stage I anal cancer</keyword>
  <keyword>stage II anal cancer</keyword>
  <keyword>stage IIIA anal cancer</keyword>
  <keyword>stage IIIB anal cancer</keyword>
  <keyword>stage IV anal cancer</keyword>
  <keyword>localized extrahepatic bile duct cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>localized gallbladder cancer</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>localized gastrointestinal carcinoid tumor</keyword>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>regional gastrointestinal carcinoid tumor</keyword>
  <keyword>gastrointestinal stromal tumor</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized resectable adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>metastatic extrahepatic bile duct cancer</keyword>
  <keyword>metastatic gallbladder cancer</keyword>
  <keyword>stage IA gastric cancer</keyword>
  <keyword>stage IB gastric cancer</keyword>
  <keyword>stage IIA gastric cancer</keyword>
  <keyword>stage IIB gastric cancer</keyword>
  <keyword>stage IIIA gastric cancer</keyword>
  <keyword>stage IIIB gastric cancer</keyword>
  <keyword>stage IIIC gastric cancer</keyword>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage IIA colon cancer</keyword>
  <keyword>stage IIB colon cancer</keyword>
  <keyword>stage IIIA colon cancer</keyword>
  <keyword>stage IIIB colon cancer</keyword>
  <keyword>stage IIIC colon cancer</keyword>
  <keyword>stage IVA colon cancer</keyword>
  <keyword>stage IVB colon cancer</keyword>
  <keyword>stage I rectal cancer</keyword>
  <keyword>stage IIA rectal cancer</keyword>
  <keyword>stage IIB rectal cancer</keyword>
  <keyword>stage IIC rectal cancer</keyword>
  <keyword>stage IIIA rectal cancer</keyword>
  <keyword>stage IIIB rectal cancer</keyword>
  <keyword>stage IIIC rectal cancer</keyword>
  <keyword>stage IVA rectal cancer</keyword>
  <keyword>stage IVB rectal cancer</keyword>
  <keyword>stage IA esophageal cancer</keyword>
  <keyword>stage IB esophageal cancer</keyword>
  <keyword>stage IIA esophageal cancer</keyword>
  <keyword>stage IIB esophageal cancer</keyword>
  <keyword>stage IIIA esophageal cancer</keyword>
  <keyword>stage IIIB esophageal cancer</keyword>
  <keyword>stage IIIC esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

